An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerExtended lymph node dissection in robotic radical prostatectomy: Current statusOne is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason gradingCurrent technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomyBeyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.Multi-parametric magnetic resonance imaging as a management decision tool.Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer.Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience.Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer: comparison between EORTC prostate cancer radiotherapy guideline, RTOG0815 protocol and actual anatomy.Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis.Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.Predictive factors for lymph node positivity in patients undergoing extended pelvic lymphadenectomy during robot assisted radical prostatectomy.Preclinical Evaluation of Intraoperative Low-Energy Photon Radiotherapy Using Spherical Applicators in Locally Advanced Prostate CancerOptimizing the management of high-risk, localized prostate cancerPersonalized management in low-risk prostate cancer: the role of biomarkers.ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.The genomic landscape of prostate cancerCharacteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland.Prostate cancer nomograms: a review of their use in cancer detection and treatment.Key papers in prostate cancer.Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Gleason and Fuhrman no longer make the grade.Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know.Prostate cancer risk stratification with magnetic resonance imaging.Predictors for Permanent Medialization Laryngoplasty in Unilateral Vocal Fold Paralysis.From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer.Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.Sentinel node biopsy and lymphatic mapping in penile and prostate cancer.Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy.Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma.Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis.ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.Accurate prediction tools in prostate cancer require consistent assessment of included variables.
P2860
Q26747782-50739817-39C1-4B69-B96B-FBF54EE835A5Q26749073-4D194AF0-F6B1-46D7-B0B0-B0063DB20B95Q28070143-39C727E8-2BBD-42C6-A542-BA1F14E23347Q28075727-F1839A1B-914E-4597-B7D3-155FAA8CC3B9Q28079221-E6CB383E-7193-46C6-87DF-221243E2C1DFQ33765122-9479DD63-D57F-4837-8EFF-C2B6F19F0F70Q33890160-CEFDDF79-1C6D-4818-8F65-2AA47051F839Q34371639-5435A3C0-950A-418F-9D5D-45A935728980Q34735844-C7E46AC6-BBDF-454D-A4AA-B84BF1C192CEQ34987841-60FE3680-A66C-4E75-87D4-0D55383C2281Q35236283-1B55A891-1288-47D5-8CCF-B7FD59A0415FQ35536948-87453C03-DA2B-4F3C-9C72-85B63AEB95E3Q35566861-C8ECC3AC-30CF-4798-88B7-5855A37239C6Q35830328-95A93874-4DD8-411B-9FCE-560736EBD788Q36059956-B6E4749E-D28F-40C1-9A6A-42390AA7329AQ36492451-3958111D-E944-4900-BA0E-3449B3341C09Q36495701-05D23975-DC1F-434C-A4BF-E2815B44411CQ36741911-55C407CB-FEC1-4625-A9DC-4485F22AE988Q37146163-AD644398-6D83-459D-A06C-06034EC64574Q37689245-A254896B-22B6-4C92-9576-4FDED59ED74CQ38109474-FFE26DE9-CFD1-48A1-921E-A49350E75C2AQ38152998-874F27C9-D604-4194-9491-E9C168EE1D34Q38181000-A80C06AC-55B5-4B48-B3DD-D9F6E3630701Q38263031-ED39BDE2-22CF-4D23-82F5-F59D85719A0CQ38321182-4A46A25C-DAC6-4A93-AEC2-0D10D5EBA4C8Q38565256-E3841896-8388-446D-8654-B491E81DF852Q38588658-9E0F6D9F-A7B9-4C44-8FB6-2CEE2C5EC531Q38636446-1CA57CAB-D45E-4A5B-B89A-58C07802E5E3Q38796980-EBC5C8E2-7A41-4796-8E95-0159063BEF42Q38825026-11647CD6-DEA9-4F54-8931-5C23C951BA05Q38841964-65C98B7A-22B4-4EA7-9F10-4EACF4910596Q38843182-F0061EBE-9BF7-420D-86FB-FC0BB171A371Q39010629-9F74D4D6-A68F-4253-B6BC-69358C576C11Q39085006-7B89429A-EC91-4B45-A2A1-E9E58B8181B4Q39356185-86456CDD-81E8-4DBA-90CB-05A38B923E9BQ39373854-490B25BD-1A63-40A4-BB2C-1DA76B6688CEQ39394372-10368C61-099F-40AF-85FF-7EED4D3C3ABBQ39456200-B4952569-2526-49AE-9CA4-1FFA031ED614Q39639104-8155F88B-047C-4724-9338-46A4BB6E21B0Q39882385-BDCD1BAF-5D97-4CBB-A080-D3D6F0013CD2
P2860
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An updated prostate cancer sta ...... ed on cases from 2006 to 2011.
@en
An updated prostate cancer staging nomogram
@nl
type
label
An updated prostate cancer sta ...... ed on cases from 2006 to 2011.
@en
An updated prostate cancer staging nomogram
@nl
prefLabel
An updated prostate cancer sta ...... ed on cases from 2006 to 2011.
@en
An updated prostate cancer staging nomogram
@nl
P2093
P2860
P1433
P1476
An updated prostate cancer sta ...... ed on cases from 2006 to 2011.
@en
P2093
Brian M Lin
Bruce J Trock
Elizabeth B Humphreys
John B Eifler
Jonathan I Epstein
Michael T Partin
Patrick C Walsh
Zhaoyang Feng
P2860
P356
10.1111/J.1464-410X.2012.11324.X
P577
2012-07-26T00:00:00Z